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Abstract 
Objectives: Since the 2007 recommendations for the management of early arthritis have been 
presented, considerable research has been published in the field of early arthritis, mandating 
an update of the 2007 EULAR recommendations for management of early arthritis.  
Methods: In accordance with the 2014 EULAR Standardised Operating Procedures, the 
expert committee pursued an approach that was based on evidence in the literature and on 
expert opinion. The committee involved 20 rheumatologists, 2 patients and 1 health 
professional representing 12 European countries. The group defined the focus of the expert 
committee and target population, formulated a definition of “management” and selected the 
research questions. A systematic literature research (SLR) was performed by 2 fellows with 
the help of a skilled librarian. A set of draft recommendations was proposed on the basis of 
the research questions and the results of the SLR. For each recommendation the categories of 
evidence were identified, the strength of recommendations was derived and the level of 
agreement was determined through a voting process.  
Results: The updated recommendations comprise 3 overarching principles and 12 
recommendations for managing early arthritis. The selected statements involve the 
recognition of arthritis, referral, diagnosis, prognostication, treatment (information, 
education, pharmacological and non-pharmacological interventions), monitoring and strategy. 
Eighteen items were identified as relevant for future research. 
Conclusion: These recommendations provide rheumatologists, general practitioners, health 
professionals, patients and other stakeholders with an updated EULAR consensus on the 
entire management of early arthritis.  
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Peripheral inflammatory arthritis is among the most common features with which patients 
present in clinical rheumatology. Identifying the underlying disease can be difficult, 
particularly at an early stage. In clinical practice, early inflammatory arthritis is frequently 
undifferentiated (1). Early arthritis can develop into established rheumatoid arthritis (RA) or 
another definite arthropathy, can resolve spontaneously, or may remain undifferentiated for 
indefinite periods. To better evaluate diagnosis and outcome in arthritis, it has been proposed 
to first recognize inflammatory arthritis; then search for a definite diagnosis (e.g., peripheral 
or axial spondyloarthritis; psoriatic arthritis [PsA]; systemic lupus erythematosus…), and 
finally estimate the risk of developing persistent and/or erosive arthritis and propose an 
optimal therapeutic strategy (2, 3). Although the prognosis of early arthritis is still difficult to 
define, a combination of clinical, laboratory and radiographic parameters may help to predict 
patients’ outcomes with acceptable accuracy.  
The management of early arthritis has changed considerably in the past few years under the 
influence of new concepts for diagnosis and new effective therapies. Conventional synthetic 
disease-modifying anti-rheumatic drugs (csDMARDs) have been shown to slow disease 
progression in chronic inflammatory arthritides such as RA and PsA (4–6). Furthermore, 
biological (b) DMARDs have demonstrated rapid and sustained disease control associated 
with an arrest of joint destruction (7,8). A large body of evidence points to the usefulness of 
very early DMARD-start for early chronic inflammatory arthritis, preferably before the onset  
of erosions, in order to reduce or even prevent the risk of (further) joint damage and disability 
(5,9,10). Also, the assessment and tight monitoring of patients with early arthritis serves to 
better adapt therapeutic strategies (9,11). Beyond doubt, the treatment goal of early arthritis 
should now be: clinical remission and prevention of joint destruction.  
Patients with early arthritis should be identified and referred to rheumatologists to confirm 
the presence of arthritis, the (potential) diagnosis and its prognosis and initiate appropriate 
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treatment strategies based on these findings. Furthermore, management of early arthritis 
should include more than drug treatment alone, with education, shared decision making and 
the role of allied health professionals as important themes.  
A set of recommendations for the management of arthritis should address all these different 
aspects. 
The EULAR recommendations for the management of early arthritis have been published in 
2007 (9). In 2010, EULAR has presented recommendations for the management of RA with 
synthetic and biological DMARDs, which have been updated in 2013 and 2016 (12,13); in 
addition, recommendations for the management of PsA were recently published (6). While 
the latter recommendations focused on the pharmacological treatments of PsA and RA, both 
in advanced and in early disease, the 2007 recommendations for the management of early 
arthritis covered the entire spectrum of management of early arthritis, including the 
recognition of arthritis, referral, diagnosis, prognosis, classification, information, education, 
non-pharmacological interventions and monitoring of the disease process as well as 
pharmacological treatment. The systematic literature review (SLR) that has guided the 2007 
EULAR recommendations included publications up to January 2005 (9). Between 2005 and 
2015 research in early arthritis has been a major focus, and many studies have appeared in the 
peer-reviewed literature. This literature includes - but is not limited to - topics such as 
diagnosis and classification criteria, window of opportunity, imaging, prognostication, 
treatments and therapeutic strategies. 
These developments mandated an update of the existing EULAR recommendations on early 
arthritis, which is reported here. 
 
METHODS  
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The update of the EULAR recommendations for the management of early arthritis has 
followed the 2014 EULAR Standardised Operating Procedures (14). The definitions (e.g., 
management and early arthritis) of and the target populations (rheumatologists, general 
practitioners, medical students, healthcare professionals, patients) addressed by the 2007 
expert committee (9) were considered. Briefly, the term “management” was defined as “all 
organisational, diagnostic, medical and educational procedures related to patients seeking 
help for arthritis of a peripheral joint ”and“ early arthritis” was restricted to “early 
inflammatory joint disease”. 
The expert committee 
The expert committee comprised 20 rheumatologists, including 2 research fellows (CD and 
CH), 1 health professional and 2 patients, from 12 European countries.  
Fifteen research questions derived from the 2007 process were proposed by the convenor 
(BC) and the methodologist (RL), and subsequently amended and approved by the whole  
committee. The selected topics included recognition of arthritis, referral, diagnosis, 
prognostics, classification, information, education, non-pharmacological interventions, 
pharmacological treatments, monitoring of the disease process, strategy and prevention.  
 
Evidence-based approach 
The research questions were adjusted for further literature research if appropriate, and 
structured according to the Patients – Intervention – Comparator - Outcome (PICO) 
systematic by 4 of the authors (CD, CH, BC, RL). Eligible study types were also defined. 
A systematic search of PubMed, Medline, Embase, CINAHL and the Cochrane library was 
performed, with the help of a skilled librarian (Louise Falzon, Columbia University Medical 
Centre, USA). All articles published in English up to December 2015 were included. 
Abstracts from the 2014 and 2015 EULAR and American College of Rheumatology (ACR) 
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conferences were also considered. The search was completed by a hand search and by 
questioning experts for additional references. The SLR process is reported in detail in two 
separate articles (15,16). 
Expert opinion approach 
Each member of the expert committee obtained insight into the results of the literature search 
and the accompanying levels of evidence before a meeting in January 2016. During the 
meeting, the results of the SLR were presented to the committee in aggregated format. Three 
break-out groups, chaired by one expert, were formed to amend the 2007 recommendations 
(1-4; 5-8 and 9-12) and to propose new recommendations if considered appropriate. Each 
group then reported its proposals and wording to the entire committee for discussion and 
consensus, and the final formulation of the recommendations was obtained after a vote with 
at least 85% agreement for each item’s final wording. 
After the meeting the recommendations were circulated by email to all expert committee 
members for further minor amendments if necessary. Categories of evidence and grades of 
recommendations were then determined (by CD, CH, RL, BC) according to the standards of 
the Oxford Centre for Evidence-Based Medicine (17). To determine the level of agreement 
with recommendations, an anonymized email-based voting on a 0–10 scale was performed, a 
vote of 0 indicating complete disagreement with a particular recommendation and 10 
indicating complete agreement. The means and SDs for scores from the whole group were 
calculated. The recommendations are presented as a bulleted list and as a flow diagram of the 
various management steps (table 1; figure 1).  
 
RESULTS 
The discussions of the expert committee resulted in 3 overarching principles and 12 
recommendations (Table 1) (in 2007, 12 recommendations were formulated).  
 10
 
Overarching principles 
 
The expert committee considered that some of the principles on the care of patients with early 
arthritis are generic and should be stated first and separated from individual recommendations 
on diagnosis, prognosis and treatment. The committee decided unanimously on the following 
3 overarching principles (Table 1). 
 
Principle A: 
 
Management of early arthritis should aim at the best care and must be based on a shared 
decision between the patient and the rheumatologist. 
 
The term “best care” is obviously a major principle in medicine. The wording “shared 
decision between the patient and the rheumatologist“ is more than informing the patient; it 
rather refers to the comprehensive process of communication, knowledge exchange and 
achieving consensus that should lead to a treatment decision that is optimal from the 
perspectives of both patient and clinical care provider.  
 
Principle B: 
 
Rheumatologists are the specialists who should primarily care for patients with early 
arthritis. 
 
This statement, which was part of recommendation 1 in the 2007 recommendations, was also 
highlighted in the EULAR recommendations for the management of RA (14) and PsA (6). Its 
basis is evidence that patients with chronic arthritis under rheumatologists’ care receive an 
earlier diagnosis, start treatment earlier, and have better outcomes, in particular with respect 
to joint damage and physical function (18–20). Rheumatologists have the expertise to 
establish an accurate diagnosis of early arthritis, are familiar with monitoring disease activity 
and with the potential severity of the disease in their patients with inflammatory arthritis, and 
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are well aware of the indications, contraindications and adverse effects of specific therapies. 
However, the expert committee intentionally added the term “primarily” to this statement for 
three reasons: 1) the management of patients with early arthritis includes the care by primary 
care physicians and other health professionals in a multidisciplinary approach; 2) in some 
places care by rheumatologists is not always available and accessible. Some countries have a 
shortage of rheumatologists, and in such situations patients should receive treatment from 
other health care providers with experience in the care of patients with inflammatory arthritis. 
3) in some countries, task shifting from rheumatologists to other health professionals is 
actively supported in order to facilitate  early access and optimal quality of care, and to make 
care cheaper.  Such care is still primarily under the responsibility and supervision of 
rheumatologists, but may be provided by other care providers. 
 
Principle C:  
 
A definite diagnosis in a patient with early arthritis should only be made after a careful 
history taking and clinical examination, which should also guide laboratory testing and 
additional procedures. 
 
In the 2007 recommendations, this important statement was included as bullet point 3. It was 
considered that “good clinical practice” and a “high level of training” suffices, an opinion 
that was entirely expert-based. The expert group was of the unanimous opinion that the 
statement is so generic that it represents an overarching principle rather than a 
recommendation. To establish a definite diagnosis in a patient with early arthritis, the group 
proposed that the minimum diagnostic procedures should include careful history taking and 
clinical examination, keeping the different possible causes of inflammatory arthritis in mind. 
After excluding other causes of joint swelling and pain (e.g., septic arthritis, trauma, 
osteoarthritis, gout) particular attention should be paid to age, geographical area and travel 
history, number and pattern of involved  joints, axial/entheseal involvement and extra-
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articular features (e.g., eye, skin, genito-urinal and gastrointestinal symptoms), including 
recent infections (1). A minimal laboratory testing panel was proposed in the 2007 
recommendations and should include testing for C-reactive protein (CRP)/erythrocyte 
sedimentation rate (ESR), full blood cell count, transaminase levels, renal function, and urine 
analysis, rheumatoid factor (RF), anti-citrullinated peptide antibodies (ACPA) and anti-
nuclear antibodies. In addition, the diagnostic procedure may be expanded with microbiology 
and/or serological tests (reactive arthritis, synovial fluid microbial culture, Lyme disease, 
parvovirus infection, hepatitis B or C), uric acid testing, synovial fluid analysis (cell count 
and polarized light microscopy if needed), chest and joint radiographs, but dependent on the 
context and the country.  
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Table 1: 2016 update of the EULAR recommendations for management of early 
arthritis: Final recommendations based on evidence and expert opinion 
 
Overarching principles 
A. Management of early arthritis should aim at the best care and must be based on a shared 
decision between the patient and the rheumatologist  
B. Rheumatologists are the specialists who should primarily care for patients with early 
arthritis  
C. A definitive diagnosis in a patient with early arthritis should only be made after a careful 
history taking and clinical examination which should also guide laboratory testing and 
additional procedures  
 
Recommendations 
 
1. Patients presenting arthritis (any joint swelling, associated with pain or stiffness) should 
be referred to, and seen by, a rheumatologist, within six weeks after the onset of 
symptoms.  
2. Clinical examination is the method of choice for detecting arthritis, which may be 
confirmed by ultrasonography.  
3. If a definite diagnosis cannot be reached and the patient has early undifferentiated 
arthritis, risk factors for persistent and/or erosive disease, including number of swollen 
joints, acute phase reactants, rheumatoid factor, ACPA and imaging findings, should be 
considered in management decisions. 
4. Patients at risk of persistent arthritis should be started on DMARDs as early as possible 
(ideally within 3 months), even if they do not fulfil classification criteria for an 
inflammatory rheumatologic disease.  
5. Among the DMARDs, methotrexate is considered to be the anchor drug and, unless 
contraindicated, should be part of the first treatment strategy in patients at risk of 
persistent disease.  
6. NSAIDs are effective symptomatic therapies but should be used at the minimum 
effective dose for the shortest time possible, after evaluation of gastrointestinal, renal, 
and cardiovascular risks.  
7. Systemic glucocorticoids reduce pain, swelling and structural progression, but in view of 
their cumulative side effects, they should be used at the lowest dose necessary as 
temporary (less than 6 months) adjunctive treatment. Intra-articular glucocorticoid 
injections should be considered for the relief of local symptoms of inflammation.  
8. The main goal of DMARD treatment is to achieve clinical remission, and regular 
monitoring of disease activity, adverse events and comorbidities should guide decisions 
on choice and changes in treatment strategies to reach this target.  
9. Monitoring of disease activity should include tender and swollen joint counts, patient 
and physician global assessments, ESR and CRP, usually by applying a composite 
measure. Arthritis activity should be assessed at one to three month intervals until the 
treatment target has been reached. Radiographic and patient-reported outcome measures, 
such as functional assessments, can be used to complement disease activity monitoring.  
10. Non-pharmacological interventions, such as dynamic exercises and occupational 
therapy, should be considered as adjuncts to drug treatment in patients with early 
arthritis.  
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11. In patients with early arthritis smoking cessation, dental care, weight control, assessment 
of vaccination status and management of comorbidities should be part of overall patient 
care. 
12. Patient information concerning the disease, its outcome (including comorbidities) and its 
treatment is important. Education programs aimed at coping with pain, disability, 
maintenance of ability to work and social participation may be used as adjunct 
interventions. 
NSAIDs, non-steroidal anti-inflammatory drugs; ACPA, anti-citrullinated peptide antibodies; DMARD, disease-
modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein 
 
 
 
 
Recommendations  
 
The discussions of the expert committee culminated into 12 recommendations (Table 1). In 
comparison with 2007, the previous recommendation 3 was transformed into overarching 
principle C, while a recommendation for prevention (No. 11) was added. In addition, the 
order of the bullet points was slightly amended in order to better assure a logical sequence 
(and not for reasons of prioritization).  Table 2 displays the levels of evidence and grades for 
the following recommendations based on the Oxford Levels of Evidence assessment as well 
as level of agreement after anonymized voting by the expert committee. 
 
Recommendation 1: 
 
Patients presenting with arthritis (any joint swelling, associated with pain or stiffness) 
should be referred to, and seen by, a rheumatologist, within six weeks after the onset of 
symptoms.  
 
This recommendation is almost identical to its 2007 counterpart, but with subtle changes in 
the wording. After 2005,  2 studies have confirmed that  patients with inflammatory arthritis 
in general, and those with suspected RA in particular, should be referred to rheumatologists 
as early as possible (19,20). A delay in referral is one of the most important causes of late 
diagnosis and late start of effective treatment. Patients with early arthritis referred to a 
 15
specialist within 3 months show better outcomes in terms of drug-free remission, 
radiographic damage and (less) need for orthopaedic surgery than those with late 
referral.(15). This is also fully in line with standards of care developed for patients with RA 
and quality indicators as established by European Expert committees (21).On the basis of 
these data as well as the clinical experience of the committee members it was recommended 
that diagnosis and start of treatment, both by a rheumatologist, should be established within a 
relatively short period after the onset of complaints which justifies the wording “within 6 
weeks” in this recommendation. 
Joint swelling not due to trauma or bony swelling suggests early inflammatory arthritis, 
especially if associated with pain and morning stiffness >30 min (22). Several referral 
questionnaires evaluating swelling, pain and stiffness have been developed to aid in the  
detection of early arthritis (15). These questionnaires have a good sensitivity (86-90%) and 
specificity (90%), but have been tested only in small patient samples and lack confirmation in 
independent validation cohorts. The committee was of the opinion that an appropriately 
validated tool to help general practitioners in adequately diagnosing and referring patients 
with early arthritis is currently lacking. The strength of this recommendation was considered 
‘good’ (category B) (Table 2). 
 
Table 2: Updated EULAR recommendations for management of early arthritis, with level of 
evidence (LoE), grade of recommendation (GoR) and level of agreement (LoA) 
 
LoE* GoR* LoA* 
A. Shared decision  na na 9.87 ± 0.46 
B. Rheumatologists na na 9.78 ± 0.67 
C. Diagnosis na na 9.78 ± 0.67 
1. Early referral Ib B 9.43 ± 1.16 
2. Clinical examination IIb C 9.48 ± 0.99 
3. Prognosis IIb C 9.83 ± 0.49 
4. Early treatment start Ia A 9.35 ± 1.07 
5. MTX, the anchor drug Ia A 9.52 ± 0.99 
6. NSAIDs IV D 9.00 ± 1.13 
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7. Glucocorticoids Ia A 9.00 ± 1.28 
8. Remission and treatment strategies Ib,IV** A,D 9.52 ± 0.9 
9. Regular monitoring Ia,IV A,D$ 9.13 ± 1.06 
10. Non-pharmaceutical interventions 1a B 8.96 ± 1.26 
11. Prevention IIb,IV C,D$ 8.96 ± 1.19 
12. Patient information Ia,Ib B 9.35 ± 0.98 
* LoE and GoR are based on the recommendations of the Oxford Centre for Evidence-Based 
Medicine. LoA was based on an anonymized email voting system with a 0-10 scale by all 
members of the expert committee (data are mean ± SD; 100% of voters) 
** The general statement is evidence-based. 
$ The place in the treatment algorithm is based on expert consensus. 
na, not applicable; MTX, methotrexate 
 
 
 
 
 
 
Recommendation 2: 
 
Clinical examination is the method of choice for detecting arthritis, which may be 
confirmed by ultrasonography. 
 
The expert committee unanimously appreciated the pivotal role of clinical examination. 
Clinical examination is still the cornerstone of detecting synovitis. This appreciation does not 
preclude that imaging modalities may be more sensitive in the detection of synovitis. 
Ultrasonography (US), including power Doppler techniques, may suggest synovitis by 
showing thickening of the synovial membrane, bursae and/or tendon sheaths with enhanced 
vascularity (15). Several controlled studies have suggested a greater sensitivity of US than 
clinical examination in detecting synovitis in the knee and in small joints. US has been 
evaluated in detail in the “EULAR recommendations for the use of imaging of the joints in 
the clinical management of rheumatoid arthritis” (23). The expert committee did not 
recommend a more prominent role for US in the detection of synovitis, since it was broadly 
felt that potentially decreased specificity and lack of knowledge regarding the long-term 
consequences of positive US in individual patients did not currently justify a more prominent 
position for US.  Further, wording specifically referring to power Doppler was deleted, 
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because the group considered that power Doppler should be part of every US joint 
examination anyway. 
MRI has also been suggested to be more sensitive than clinical examination in the early 
detection of synovitis (23-25) but may face a lack of specificity as suggested by the 
prevalence of MRI abnormalities in the normal population (26). In contrast with US, which is 
now a common tool in many rheumatologist practices, the long scanning time, limited access 
and the relatively high costs limit the widespread use of MRI. Therefore, the expert 
committee considered that MRI should be proposed only in very difficult cases or in patients 
with specific forms of arthritis, and that further research is needed to better determine the 
place of this imaging modality in the diagnosis of patients with early arthritis. MRI was part 
of the 2007 recommendations but was deleted from the current set. 
 
Recommendation 3: 
 
If a definite diagnosis cannot be reached and the patient has early undifferentiated 
arthritis, risk factors for persistent and/or erosive disease, including number of swollen 
joints, acute-phase reactants, rheumatoid factor, ACPA and imaging findings, should be 
considered in management decisions. 
 
This recommendation was slightly rephrased because the group wanted to highlight that early 
undifferentiated arthritis should be clearly differentiated from early RA. In addition, 
“imaging” was used instead of “radiographic” to show that imaging modalities other than 
plain radiographs may provide prognostic information. For patients with early arthritis, after 
the exclusion of specific forms of arthritis, the working diagnosis is often undifferentiated 
arthritis. The next step in the diagnostic procedure is to evaluate the risk of persistent and/or 
erosive arthritis, usually corresponding to the definition of RA, in an individual patient (27). 
This prognostic typing is now considered crucial to guide the optimal therapeutic strategy.  
Since the 2007 exercise, many observational studies have evaluated the prognostic value of 
laboratory and imaging procedures for early arthritis. Most prognostic factors were analysed 
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in a multivariate manner in these studies, to test their independent contribution. Commonly 
tested dependent variables were persistence, erosiveness or radiographic progression. 
In most of the studies, ACPA- and RF-positivity and ACPA- and RF-levels have shown some 
predictive value for the development of persistent and erosive arthritis. This observation was 
clearly highlighted by EULAR and ACR since ACPAs, in addition to RF, have obtained an 
important weight in the 2010 ACR/EULAR classification criteria for RA (27,28). In addition, 
several recent studies have confirmed the independent association of ACPAs with a diagnosis 
of RA as well as with radiographic progression in patients with early arthritis (29-33). RF has 
been assigned a similar weight as ACPAs in the 2010 ACR/EULAR classification criteria for 
RA, although recent publications stemming from early arthritis cohorts and observational 
studies have suggested a lower predictive and diagnostic value of RF compared to ACPAs 
but RF has a stronger association with disease activity independent of the presence of ACPA 
(15). The combination of RF and ACPAs does not provide additional value to RF or ACPAs 
alone (28). In addition to ACPA, the number of swollen joints and the level of CRP and ESR 
are independent contributory factors.  
Early erosion typical of RA is still a major prognostic factor in early arthritis and 
automatically leads to a classification of RA (27,34). Synovitis and erosion detected by MRI 
or US may predict further joint damage in early arthritis, but false positivity has been 
reported (26, 35). MRI-detected bone marrow oedema and osteitis are independent predictors 
of radiographic progression in early RA (23,24), but data are limited in early arthritis. Finally, 
2 recent studies have shown that hand flexor or extensor tenosynovitis on US (36) or MRI 
(25) may be a specific- though not very sensitive - marker for RA classification. 
Several combinations of diagnostic markers have been evaluated but no one has been 
formally validated (15). In addition, multibiomarker tests have been proposed to evaluate 
disease activity, prognosis and response to therapy, but current data are not convincing and 
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further research is warranted (15). Finally, it has been reported that substituting MRI for 
clinical examination in the 2010 ACR/EULAR criteria increases the sensitivity but decreases 
the specificity for a diagnosis of RA (15). MRI is therefore of limited value in making a 
diagnosis of RA and is not recommended as a standard procedure. 
 
Recommendation 4: 
 
Patients at risk of persistent arthritis should be started on DMARDs as early as possible 
(ideally within 3 months), even if they do not fulfil classification criteria for an 
inflammatory rheumatologic disease.  
 
This recommendation was slightly reworded and reiterates the unanimous opinion of the 
committee that an early treatment start is pivotal in the management of patients with early 
chronic arthritis such as early RA, early PsA, or those at risk to develop persistent and erosive 
disease. The wording “RA” is not used in this statement, but the implicit meaning is that 
persistent and/or erosive disease is factually synonymous to RA (see previous item) and 
justifies an early start with DMARDs. A new element is the maximum delay of 3 months 
after the onset of symptoms before starting the first DMARD. The expert committee was of 
the opinion that this time frame constitutes a ‘window of opportunity’ that should be 
considered to provide an optimal outcome in the patients at risk. Eight recent studies have 
endorsed an early treatment start. Four studies showed that introducing DMARDs within 3 
months after the onset of symptoms leads to better outcome (remission, response to 
treatment, Health Assessment Questionnaire [HAQ] disability score or radiographic 
progression) (37-40). Very recently, van Nies et al. have suggested, based on data in the 
ESPOIR and Leiden early-arthritis cohorts, that 12 to 14 weeks represent an appropriate 
window within which therapy should be started in order to prevent arthritis persistence (41). 
In addition, disease duration at the time of DMARD initiation was the most important 
determinant of response to DMARD therapy in another study (15). This statement may raise 
questions about the best definition for ‘early RA’. A duration of 3 months after the onset of 
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symptoms may be the longest allowable delay in prescribing the first DMARD. However, 
this maximum delay is still difficult to meet in daily practice, while most of the recent ‘early 
RA-cohorts’ allowed a delay of 6 months from the onset of symptoms (joint swelling usually) 
for inclusion (28,29,41). A delay of not more than 6 months was also proposed in recent RA 
guidelines (42). A delay of more than one year from symptom onset must not be considered 
“early” anymore. 
 
Recommendation 5: 
 
Among the DMARDs, methotrexate is considered the anchor drug and unless 
contraindicated, should be part of the first treatment strategy in patients at risk of 
persistent disease.  
 
This recommendation (previously No. 9) remains almost unchanged. Previous SLRs have 
confirmed the clinical and structural efficacy as well as the good safety profile of 
methotrexate (MTX) (4,43,44). An important argument to consider MTX an anchor drug as 
part of the first treatment strategy in patients at risk of persistent arthritis (e.g., at risk of RA) 
is its good efficacy in early RA, and its ‘practicability’, both as monotherapy and in 
combination with glucocorticoids, other csDMARDs and bDMARDs) (4,13,45). Recent trials 
in early DMARD-naïve RA patients have evaluated MTX monotherapy versus csDMARDs 
combined with different dosages and routes of administration of glucocorticoids. 
Verschueren et al. have recently reported similar 16-week remission rates in high-risk early-
RA patients receiving MTX-monotherapy, MTX plus sulfasalazine (SSZ) or MTX plus 
leflunomide (LEF), all in combination with high-dose prednisone bridging strategies  (46). In 
another trial MTX plus temporary high-dose prednisone was not less effective than MTX 
plus SSZ plus temporary high-dose prednisone after 26 weeks (47). The tREACH trial 
suggested short lived superiority of MTX combined with SSZ, hydroxychloquine (HCQ) and 
glucocorticoids versus MTX and glucocorticoids, but this superiority was not seen in all 
aspects, was not clinically meaningful and did ultimately not sustain after 1 year (48). The 
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TEAR trial did not support a benefit of an intensive csDMARDs combination regimen over 
MTX-monotherapy either (49). In the absence of clear signals for superiority of a 
csDMARDs combination regimen, and guided by a trend towards lower tolerability for 
csDMARD-combination (16), the committee was of the opinion that the first treatment 
strategy should be MTX monotherapy with or without short term high dose glucocorticoids 
as bridging therapy for most patients. In that regard, dose optimization is an important aspect 
of first-line DMARD strategy, as previously reported (4,45) (MTX should be titrated rapidly 
to 20-30 mg/week, depending on clinical response and tolerability; parenteral administration 
should be considered in case of inadequate clinical response or intolerance). 
The superiority of bDMARDs plus MTX over MTX monotherapy has been proven in many 
randomized controlled trials (RCTs) and was confirmed by 8 recent studies in the current 
SLR (16). In addition, 2 targeted synthetic DMARDs have recently demonstrated superiority 
to MTX, both used as monotherapy, in patients with early RA (50,51). Nevertheless, because 
the benefit-to-risk ratio of these biologic and targeted synthetic DMARDs was not 
convincingly favourable in patients with early disease, because tight monitoring is anyway 
part of the current treatment strategy to identify those in need of adding biologics and also 
because of their high cost, the expert committee considered their use as a first treatment 
strategy inappropriate, except in rare situations. 
Recent RCTs comparing other csDMARDs to MTX were lacking. The clinical efficacy of 
LEF, and to a lesser extent SSZ, is similar to MTX in established and recent RA (9). LEF is 
as effective as MTX in slowing radiographic damage, and its therapeutic maintenance is 
similar to that of MTX (9) In contrast, SSZ may be inferior to LEF and MTX in the long 
term. Although formal evidence prioritizing MTX over other csDMARDs as the first 
DMARD used in early arthritis and/or early RA is lacking, the expert committee does 
recommend MTX as first-choice treatment (unless contra-indicated) in patients at risk of 
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persistent disease. LEF and (to a lesser extent) SSZ are considered the best alternatives. Of 
note, SSZ is considered safe during pregnancy in contrast to MTX and LEF. Finally, the 
committee is of the opinion  that antimalarial drugs, which have shown less clinical efficacy 
and may not retard radiographic progression in patients with RA but may have positive 
metabolic effects, can be considered as partner in combination therapy or as DMARD 
monotherapy in patients with mild disease and comorbidities or with persistent arthritis other 
than RA (52). 
 
Recommendation 6: 
 
NSAIDs are effective symptomatic therapies, but should be used at the minimum effective 
dose for the shortest time possible, after evaluation of gastrointestinal, renal and 
cardiovascular risks.  
 
The SLR did not yield new data on NSAIDs in patients with early arthritis. The expert 
committee felt that symptomatic therapy with NSAIDs is still of value in patients presenting 
with early arthritis, but only after a careful consideration of gastrointestinal, renal and 
cardiovascular contraindications. In addition to the previous item no 7 about NSAIDs, the 
group now reinforces the need to follow US Food and Drug Administration and European 
Medicines Agency guidelines about NSAIDs, that now includes wording about the  shortest 
possible treatment duration, the minimum effective dose and the contra-indications for 
patients at risk (www.fda.gov; www.ema.europa.eu).  
 
Recommendation 7: 
 
Systemic glucocorticoids reduce pain, swelling and structural progression, but in view of 
their cumulative side effects, they should be used at the lowest dose necessary as temporary 
(less than 6 months) adjunctive treatment. Intra-articular glucocorticoid injections should 
be considered for the relief of local symptoms of inflammation.  
 
The expert committee has intensively debated the role of glucocorticoids in the management 
of early arthritis.  This discussion was based on expert opinion and on new information 
obtained by the SLR (16). Recently, one meta-analysis of 14 RCTs in patients with RA and 2 
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RCTs in patients with ‘early RA’ has confirmed that systemic glucocorticoids (GC) improve 
clinical and radiographic outcomes (16, 53, 54).  Preferably, therapy with systemic GC is 
temporary because of the risk of side-effects, including weight gain, hypertension, diabetes, 
cataracts and osteoporosis, which justify careful monitoring and appropriate prevention. New 
data stemming from registries, observational studies and extensions of RCTs have also 
suggested an increased risk of severe infections, cardiovascular events and mortality (16, 55-
60). In addition, there is evidence that intra-articular steroids may be an effective adjunct to 
DMARDs in relieving joint symptoms in patients presenting with early arthritis and may 
improve disease activity up to 24 months (16). 
The committee has reworded this item (No. 8 in the previous recommendations) in order to 
highlight the effectiveness of systemic GC for relieving symptoms and disease progression 
but also in order to point to the risks of cumulative side effects in the medium to long term. 
The committee is of the opinion that GC can only be justified if used at the lowest possible 
cumulative dose, and for the shortest possible duration, and exclusively as adjunct (or: 
bridge) therapy to csDMARDs.  GC monotherapy may mask disease activity before a 
diagnosis has been established and should be avoided in patients with early arthritis, in order 
to expedite a proper diagnosis, and secure an adequate prognosis and a prompt DMARD 
treatment start. Despite a fierce debate this recommendation was finally approved by 95% of 
the members and obtained a high level of agreement (mean of 9.00 ± 1.28) with anonymous 
voting. The wording “low dose” and the optimal regimen (low daily dose or high dose then 
step-down or parenteral boosts) in early arthritis are still under debate and will be mentioned 
in the research agenda (table 3). 
Recommendation 8: 
The main goal of DMARD treatment is to achieve clinical remission, and regular 
monitoring of disease activity, adverse events and comorbidities should guide decisions on 
choice and changes in treatment strategies to reach this target.  
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The 2007 recommendations for patients with early arthritis were among the first guidelines to 
highlight clinical remission as the main objective in the care of these patients. In the past 10 
years, accumulating data have supported this as a major goal for the treatment of RA and 
other inflammatory arthritides (6,9,11,13,61). 
The expert committee has decided to keep the wording of the previous recommendation No. 
10 unchanged. A few new studies have confirmed that achieving clinical remission as early 
as possible results in better clinical outcomes and quality of life, and helps to prevent further 
structural damage, functional disability and job-loss in patients with early arthritis and early 
RA (62). Which particular remission criteria should be used in practice remains unclear. 
Composite scores (DAS, DAS28, CDAI, SDAI) should be used, and the ACR-EULAR 
remission criteria (Boolean or SDAI) is likely the most stringent (63). An interesting 
definition for daily practice is “the absence of signs and symptoms of significant 
inflammatory disease activity”(11). Recent evidence has suggested that remission leads to a 
better outcome than low disease activity (LDA) (62, 64, 65), and the committee was of the 
opinion  that clinical remission according to the ACR-EULAR Boolean or index-based 
definition is the target for every patient presenting with early arthritis. A low disease activity 
state (LDA) could be an appropriate alternative goal only in cases in which remission is 
considered unfeasible. In this respect, factors such as comorbidities, age or adverse events 
must be considered, and may determine the desired treatment target, which will form the 
basis for the process of shared decision making with the patient. 
The expert committee also discussed whether imaging remission should be included in the 
target, as suggested by some recent recommendations (23). Studies have suggested that on-
going inflammation seen by US, and to a lesser extent by MRI, in patients with clinical 
remission may predict structural progression. However, the significance thereof and its 
clinical utility are questionable and is associated with significant overtreatment and thus 
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potential waste of societal resources (66);  the SLR did not yield new information (15,16). 
Therefore, the expert committee suggested that the value of imaging remission should be part 
of the research agenda. 
Finally, the committee felt that disease activity should be closely monitored in order to allow 
a timely change in DMARD therapy when necessary. The benefits of  the treat-to-target 
approach have now amply been shown in patients with RA and PsA (11, 67)) and there is no 
reason to assume that the situation is different for early arthritis. 
 
Recommendation 9: 
 
Monitoring of disease activity should include tender and swollen joint counts, patient’s and 
physician’s global assessments, ESR and CRP, usually by applying a composite measure. 
Arthritis activity should be assessed at one to three month intervals until the treatment 
target has been reached. Radiographic and patient reported outcome measures, such as 
functional assessments can be used to complement disease activity monitoring. 
 
In every patient with active arthritis, closely monitoring disease activity is now considered of 
particular importance in the therapeutic strategy to provide a good outcome and this is 
highlighted by all of the most recent recommendations (6, 9, 11, 13, 42, 61). Monitoring 
disease activity should be as frequent as the level of disease activity mandates, usually every 
1 to 3 months, then potentially less frequently (such as every 6 to 12 months) once the 
treatment target has been achieved. 
Nevertheless, three changes were proposed to this item (previously No. 12). First, a 
composite measure was recommended as the method of choice to monitor disease activity; 
second, a specific time frame for monitoring structural damage was deliberately left out; and 
third, patient-reported outcomes were expanded beyond functional assessments. 
Swollen joint count and progression of joint damage have been consistently found to be 
associated (68, 69). In addition, many trials have supported the use of a tight control of 
disease activity assessed via composite measures that include joint count evaluation (11,16, 
67, 70). Although it is difficult to formally investigate, the expert committee was of the 
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opinion that monitoring the occurrence of radiographic progression is useful in view of one of 
the key objectives of managing early arthritis: the prevention of joint destruction. The 
determination of an optimal window for monitoring progression was added as an item for the 
research agenda (table 3). 
Finally, patient-reported outcomes such as quality of life, fatigue and physical function are 
key to evaluate outcome (71, 72) and the committee has mandated them as part of disease 
monitoring. 
Table 3: Research agenda for management of early arthritis  
 
 
Diagnosis and prognosis 
 
1. Which tools could help general practitioners to diagnose early arthritis and prioritise referral?  
 
2. Can we better define the diagnostic and prognostic value of ultrasonography  
in early arthritis? 
3.  Can we better define the diagnostic and prognostic value of MRI in early arthritis?  
4. What is the diagnostic value of the systematic screening of antinuclear antibodies in early arthritis?  
5. Which new biomarkers / multibiomarkers may help to better evaluate disease activity, the prognosis and treatment response in 
arthritis? 
 
Treatment and outcome 
 
1. Can we develop prediction models to better define the therapeutic strategy in early arthritis?  
2. Can we define at what level of risk (for developing persistent arthritis) different pharmacological 
interventions have a favorable benefit to-risk ratios?.  
3. Do combinations of csDMARDs provide a better benefit / risk ratio than csDMARD  
monotherapy in early arthritis ? 
4. Can we better define “low dose”, and “short term” use of glucocorticoids for an optimal medium  
to long term benefit to risk ratio?  
5. What is the optimal regimen (low daily dosage or high dose then step-down, or parenteral boosts)  
of glucocorticoids for better outcome in early arthritis ? 
6.  Does imaging remission have an added benefit to clinical remission in treatment decisions?  
7. What is the optimal interval at which to monitor radiographic progression in early chronic  
inflammatory arthritis? 
8. What is the effectiveness of different non-pharmacological interventions in early arthritis ? 
9. Can physical activity/exercise reduce cardiovascular risk in early chronic arthritis?  
10. Which study designs can best be used to investigate the comparative effectiveness and cost-
effectiveness of different therapeutic strategies?  
11. Is smoking cessation, oral hygiene, diets, or psychological interventions beneficial for the outcome of 
patients with early arthritis ?  
12. What are the most efficient and effective information and education interventions and exercise  
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programs for early arthritis? 
. 
 
 
 
 
Recommendation 10: 
 
Non-pharmacological interventions, such as dynamic exercises and occupational therapy, 
should be considered as adjuncts to drug treatment in patients with early arthritis.  
 
This recommendation has remained almost unchanged. The efficacy of non- pharmacological 
therapy has not been investigated in early arthritis and can only be extrapolated from the 
results of several RCTs in established RA. Hydrotherapy in patients with RA has been 
evaluated in some studies (73, 74) but with insufficient evidence to support a strong 
recommendation; consequently, hydrotherapy was not included in the current statement but 
may be considered at the individual patient level. Previous RCTs have shown that joint-
specific dynamic exercises may improve strength and physical function in RA, but the current 
SLR identified some controversial effects on disease activity (16, 74). Occupational therapy 
may improve functional ability and self-management but does not have a positive effect on 
disease activity; recent studies were not found (75).  
Finally, psychological counselling can be considered in selected patients, but trials 
investigating the efficacy of psychological interventions are lacking, and the committee did 
not include counselling in the statement. Furthermore, the SLR did not identify appropriate 
trials that evaluated the effectiveness of diets. 
Since dynamic exercises, occupational therapy and to a lesser extent hydrotherapy have been 
associated with symptom relief in patients with established RA, the expert committee has 
decided to include them as adjunct therapies to pharmaceutical therapies in patients with 
early arthritis. 
 
Recommendation 11: 
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In patients with early arthritis smoking cessation, dental care, weight control, assessment 
of vaccination status and management of comorbidities should be part of overall patient 
care. 
 
This recommendation is new and largely based on expert opinion. The expert committee felt 
that during the last decade evidence has accumulated that highlights the importance of the 
management of comorbidities (e.g. cardiovascular diseases, metabolic conditions (e.g., 
hyperlipidaemia, diabetes), lung diseases, infections, malignancies, osteoporosis and 
depression) in the context of the management of early arthritis (76-82). Comorbidities may 
affect life expectancy and outcomes (physical function, quality of life) independently of 
disease activity in patients with inflammatory arthritis. In addition, coexisting diseases may 
affect the efficacy and safety of anti-rheumatic therapies (82). Obesity and smoking may 
affect the response to treatment in inflammatory arthritis (80). Prevention is now considered 
key in the management of chronic inflammatory rheumatic diseases, but comorbidities are 
still not optimally managed (76). Smoking is the best-established modifiable risk factor in the 
development of RA and spondyloarthritis (83,84). Furthermore, tobacco use has been 
associated with the presence of extra-articular manifestations such as rheumatoid nodules but 
also serum RF and ACPAs. While smoking does not seem to be associated with the 
perpetuation of disease activity or progression of RA (85), it may affect the outcome of 
spondyloarthritis (84).  
RA is associated with periodontal disease, although the direction of the relationship still 
remains unclear (86). The microbiome may play a role in chronic arthritis risk and 
progression, and Porphyromonas gingivalis infection could promote aberrant citrullination 
and a local breach of tolerance to citrullinated peptides. The potentially beneficial 
contribution of oral hygiene has been put on the research agenda. 
Although current data do not prove that risk-factor modification is beneficial to patients, the 
modifiable risk factors identified in the SLR are so generic in nature that the committee was 
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unanimously of the opinion that a recommendation aiming at abolishing their potential 
influence on arthritis (and general health) would not harm patients and may convey some 
benefits.     
In addition, the expert committee noted that fewer patients with chronic arthritis than 
recommended are currently vaccinated (87), and that this should be specifically mentioned.  
 
Recommendation 12: 
 
Patient information concerning the disease, its outcome (including comorbidities) and its 
treatment is important. Education programs aimed at coping with pain, disability, 
maintenance of ability to work and social participation may be used as adjunct 
interventions. 
 
This recommendation was very similar to the previous item no. 6. Obviously, full 
transparency about the disease and its treatment options should be an integral part of the 
management of any chronic disease, and constitutes the core of overarching principle A. 
Other healthcare providers share the responsibility in the provision of information. Studies 
have suggested that adherence to treatment is dependent on the quality of information 
exchange and the quality of the interaction between the patient and health professionals, 
including rheumatologists (16). 
EULAR has recently recommended that “people with inflammatory arthritis should have 
access to and be offered patient education throughout the course of their disease, including as 
a minimum, at diagnosis, at pharmacological treatment change and when required by the 
patient’s physical or psychological condition” (88). The content and delivery of patient 
education should be individually tailored, with individual and group sessions representing 
different approaches to delivery. It is impossible to prioritise a single educational intervention 
since all tested interventions have only short-term benefits and feature cross-national and 
cultural variations (16). Improved quality of life is a major aim for patients and the committee 
proposed to add “social participation” as one of the objectives of these education programs. 
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The expert committee also felt that patients should be aware that comorbidities may affect the 
outcome and treatment of inflammatory arthritis, and that their screening and management 
should be part of the global management of early arthritis.  
 
DISCUSSION   
 
The update of the EULAR recommendations for the management of early arthritis followed 
the 2014 EULAR Standardised Operating Procedures (14). The committee has proposed an 
important revision of the items, but obviously most major recommendations have remained 
intact. These updated recommendations for management of early arthritis contain 3 
overarching principles, 12 recommendations and 2 algorithms that integrate all the recent 
developments in the management of early arthritis. The definition of the term “management” 
was unchanged and includes all spectra of management of early arthritis, including referral, 
diagnosis, prognosis, classification, information, education, non-pharmacological 
interventions, and pharmacological treatments and monitoring of the disease. The term “early 
arthritis” was restricted to “early inflammatory arthritis” and mainly, but not only, focused on 
the risk of chronic arthritis. 
The expert committee had to face a limitation in that most of the published data on treatment 
and strategy on which they could build their recommendations involved studies in patients 
with early RA or established RA, rather than specific studies of early arthritis. Despite this 
limitation, the committee considered much of the data for early RA sufficiently robust and 
relevant for extrapolating to “early arthritis with a certain propensity to become persistent.” 
The scope was different compared to the EULAR recommendations for the management of 
RA (13), which focussed on the use of DMARDs in both early and established disease. 
However, there are overlaps with regard to the first line therapy for early arthritis at risk of 
persistence (figure 1) and for early RA (DMARD naïve and usually less than 6 months 
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disease duration). Not surprisingly, the 2 sets of recommendations are very congruent on 
these specific points. 
These recommendations have important strengths including the composition of the expert 
committee comprising 20 rheumatologists, including 2 research fellows, from 12 European 
countries and new addition of 1 health professional and 2 patient-representatives. The 
committee chose to grade the level of evidence provided by every study, which was based on 
the methodology of the study, and took this grading into consideration when discussing the 
content and the strength of the recommendations. An important consideration in the 
discussions was always whether the type of study fitted the content of the research question 
that was at the basis of the literature search. The recommendations were based on the most 
recent evidence but also on expert opinion. For example, the expert committee felt that 
evidence supported comorbidities as possibly affecting the outcome of arthritis but also 
treatment efficacy and safety and should be considered in the management of all early 
arthritis cases. Despite the sparse evidence, the expert committee also wanted to indicate that 
smoking cessation and dental care could be proposed to patients with early arthritis, and that 
both patients and health professionals should be aware of the importance to improve 
vaccination coverage. In this respect, a new recommendation on prevention was added (item 
11). Of note, the level of agreement among the experts was high for each item (means of 9.0 
to 9.9), which support the appropriateness and validity of the recommendations. 
In light of the current literature and despite important recent advances, the committee felt that 
further development of new tools is needed for early and accurate diagnosis and prognosis, 
including new biomarkers, better understanding of the added value of US and MRI, and 
creation of prediction algorithms for long-term outcome (table 3). Finally, the expert 
committee felt that the comparative effectiveness and cost-effectiveness of the different 
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strategic modalities in early arthritis, including the effectiveness of non-pharmacological 
interventions, need additional research. 
While these “recommendations” are deliberately not called “guidelines”, they do reflect a 
strong view of many European experts including patient representatives. They should provide 
rheumatologists, general practitioners, medical students, health professionals, health 
authorities and patients a practical approach to the management of early arthritis, even though 
each healthcare professional should choose the most appropriate management strategy for 
each individual patient. To that end, it is hoped that the recommendations will be widely 
disseminated and discussed within the community of rheumatologists and other health 
professionals caring for patients with early arthritis and that they will help improve the 
standard of care for patients with arthritis across different healthcare systems. Obviously, 
these recommendations will probably need amendment after about 5 years to incorporate new 
scientific evidence. 
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